Otolaryngology department patient management follow-up visit system and method

By dynamically adjusting the follow-up plan for otolaryngology patients, and evaluating pollen concentration changes using Fourier transform and weighted summing algorithms, the problem that existing systems cannot respond to peak pollen changes is solved, and the patient's treatment effect and satisfaction are improved.

CN119028609AActive Publication Date: 2024-11-26DONGGUAN EASTERN CENT HOSPITAL +1

Patent Information

Application Number
CN202411121388.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The existing otolaryngology patient management follow-up system is unable to monitor and respond to changes in pollen concentration in real time, resulting in patients not receiving timely follow-up guidance and treatment adjustments during peak pollen periods, affecting the control of the disease and treatment effect.

Method used

By obtaining the patient's symptom records and environmental pollen concentration information, the follow-up plan is dynamically generated and adjusted using the Fourier transform and weighted summing algorithm, the risk level of allergy symptoms aggravated, the personalized follow-up plan is formulated, and dynamically performed during the implementation of the plan Adjustment.

Benefits of technology

It achieves a rapid response to changes in pollen concentration, reduces fluctuations and aggravation of allergic symptoms in patients, ensures disease control, and improves treatment effect and patient treatment compliance and satisfaction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119028609A_ABST
    Figure CN119028609A_ABST
Patent Text Reader

Abstract

The invention discloses a patient management follow-up visit system and method for the otolaryngology department, and relates to the technical field of medical follow-up visit systems.The method specifically comprises the following steps that basic information, medical record records, allergy symptom description, diagnosis results and treatment schemes of patients are obtained, personal archives of the patients are established, and symptom data and allergy history of the patients are input into the system; in the pollen peak period, symptom record information and environmental pollen concentration information of all patients are obtained and analyzed after being obtained, the aggravated risk level of allergy symptoms of all the patients due to pollen concentration changes is evaluated, and all the patients are classified according to the evaluation result; according to classification results of all the patients, low-risk, medium-risk and high-risk personalized follow-up visit plans are made and implemented respectively. Through real-time data monitoring and a dynamic adjustment mechanism, the follow-up plan can be accurately evaluated and optimized, and it is ensured that the patient can obtain follow-up guidance and treatment adjustment in time when the pollen concentration suddenly changes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical follow-up systems, and in particular to an otolaryngology patient management follow-up system and method. Background Art

[0002] ENT patient management follow-up refers to the process of long-term monitoring and management of the patient's condition in a systematic way after the patient receives ENT treatment. The purpose of follow-up management is to ensure that the patient receives continuous medical guidance and support during the rehabilitation process after treatment to prevent the recurrence or deterioration of the disease and to promptly detect and deal with new health problems. This management method can help medical staff fully understand the patient's rehabilitation status, adjust the treatment plan, and improve the treatment effect. At the same time, follow-up management can also enhance the patient's compliance, prompting them to return for follow-up visits on time and follow the doctor's advice, effectively reducing the health risks caused by improper self-management. Through this systematic follow-up management, not only can the patient's quality of life be improved, but also the burden of medical resources can be reduced, and the long-term benefits of medical services can be achieved.

[0003] The existing ENT patient management and follow-up technology uses an integrated information platform to comprehensively manage and follow up patients. When the patient first visits the doctor, the system will record the patient's basic information, medical records, symptom descriptions, diagnosis results and treatment plans in detail. According to the patient's condition and treatment needs, the system will automatically generate a personalized follow-up plan and arrange specific follow-up dates and contents. When the follow-up date is approaching, the system will send reminder notifications via SMS, email or mobile phone applications to ensure that the patient attends the follow-up on time. During the follow-up process, medical staff will record the patient's latest condition, treatment effects and further diagnosis and treatment suggestions in real time, and this information will be updated to the system immediately. The system also has powerful data analysis functions, which can comprehensively analyze the patient's follow-up data and generate detailed reports to help doctors evaluate the treatment effect and adjust the treatment plan in time. The entire management process ensures patient privacy and data security through user authority management and data encryption technology, greatly improving the work efficiency of medical staff, reducing the tediousness of manual recording and reminders, and helping doctors to monitor and evaluate the patient's rehabilitation progress in real time, providing patients with more accurate and personalized medical services.

[0004] The prior art has the following deficiencies:

[0005] During the peak pollen season, the pollen concentration in the environment changes rapidly and the patient's allergic symptoms fluctuate frequently, causing the patient's actual condition to be inconsistent with the established follow-up plan. The existing technology fails to respond to these changes in pollen concentration in a timely manner, and is unable to monitor and analyze pollen concentration data in real time to generate a personalized follow-up plan. Therefore, patients fail to receive timely follow-up guidance and treatment adjustments when the pollen concentration changes suddenly, which may lead to aggravated symptoms, affect disease control and overall treatment effects. This deficiency of the existing technology not only increases the pain and medical burden of patients during the peak period, but may also lead to worsening of the disease, delay the best treatment time, and ultimately reduce the patient's quality of life and the effectiveness of medical services. At the same time, this delayed follow-up management increases the workload of medical staff, fails to effectively utilize medical resources, and affects the hospital's management efficiency and patient satisfaction.

[0006] The above information disclosed in this Background section is only for enhancement of understanding of the background of the present disclosure and therefore it may contain information that does not constitute the prior art that is already known to one of ordinary skill in the art. Summary of the invention

[0007] The purpose of the present invention is to provide an otolaryngology patient management follow-up system and method to solve the problems in the above-mentioned background technology.

[0008] In order to achieve the above object, the present invention provides the following technical solution: a method for follow-up management of otolaryngology patients, specifically comprising the following steps:

[0009] Obtain the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans, establish the patient's personal file, and enter their symptom data and allergy history into the system;

[0010] During the peak pollen season, we obtain symptom records of all patients and information on environmental pollen concentrations, analyze the information, assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and classify each patient based on the assessment results;

[0011] According to the classification results of all patients, develop and implement personalized follow-up plans for low risk, medium risk and high risk respectively;

[0012] Obtain dynamic information during the implementation of the follow-up plan, analyze it after acquisition, evaluate the implementation of the follow-up plan, and dynamically adjust the follow-up plan based on the evaluation results;

[0013] Generate follow-up reports regularly and send them to doctors and patients, while providing patients with long-term health management advice.

[0014] Preferably, during the peak pollen season, the symptom record information and environmental pollen concentration information of all patients are obtained, and analyzed after acquisition to evaluate the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and each patient is classified according to the evaluation results, specifically including the following steps:

[0015] During the peak pollen season, all patients were provided with symptom records and information on ambient pollen concentrations;

[0016] Preprocessing of all patients’ symptom records and environmental pollen concentration information;

[0017] Extracting the immune response data from the pre-processed symptom record information of each patient and the pollen concentration data from the environmental pollen concentration information, and analyzing them after extraction to generate the immune response fluctuation index and pollen concentration variation coefficient of each patient respectively;

[0018] The generated immune response fluctuation index and pollen concentration variation coefficient of each patient are used to construct an aggravation risk assessment model to generate an aggravation risk coefficient for each patient. The generated aggravation risk coefficient for each patient is compared with the pre-set aggravation risk coefficient threshold range to evaluate the risk level of each patient's allergic symptoms aggravated by changes in pollen concentration, and each patient is classified according to the evaluation results.

[0019] Preferably, the logic for obtaining the immune response fluctuation index and pollen concentration variation coefficient of each patient is as follows:

[0020] Extract the immune response data from the pre-processed symptom record information of each patient, including the immunoglobulin level values ​​and corresponding time points of each patient at different times over a period of time, and use the function MYQDB according to the time series i (T) represents the time point, MYQDB i (T) represents the immunoglobulin level of the i-th patient at time T in a period of time, i = 1, 2, 3, ..., k, k is a positive integer, and the time period is defined as [T1, T2];

[0021] Perform Fourier transform on the immunoglobulin level of the i-th patient at time T within a period of time, according to the formula:

[0022]

[0023] In the formula, F(MYQDB i (T)) is the immunoglobulin level value MYQDB at time T in the immune response data of the i-th patient with worsening symptoms i (T) frequency component, T is the time variable, f is the frequency variable, and z is the imaginary unit;

[0024] The amplitude of the Fourier transform result after taking the immunoglobulin level value of the i-th patient at time T within a period of time, that is, the absolute value |F(MYQDB i (T))|, represents the amplitude of the immunoglobulin level of the i-th patient at time T in a period of time at different frequencies;

[0025] Calculate the immune response fluctuation index of each patient. The specific calculation formula is as follows:

[0026]

[0027] Where IRFI i is the immune response fluctuation index of the i-th patient;

[0028] Extract pollen concentration data from the preprocessed environmental pollen concentration information, including the average pollen concentration of each patient's activity area at different times within a period of time, and calibrate the average pollen concentration of each patient's activity area at different times within a period of time as represents the average pollen concentration of the activity area of ​​the ith patient at time m within a period of time, m = 1, 2, 3, ..., g, where g is a positive integer;

[0029] Calculate the mean and standard deviation of the average pollen concentration in the activity area of ​​each patient over a period of time according to the formula:

[0030]

[0031] Where, HFSN i - is the average pollen concentration of the i-th patient's activity area over a period of time, is the standard deviation of the average pollen concentration in the activity area of ​​the ith patient over a period of time;

[0032] Calculate the coefficient of variation of pollen concentration for each patient. The specific calculation formula is as follows:

[0033]

[0034] Where, PCVC i is the coefficient of variation of pollen concentration of the ith patient.

[0035] Preferably, the immune response fluctuation index IRFI generated for each patient i and pollen concentration variation coefficient PCVC i Construct an exacerbation risk assessment model and generate the exacerbation risk coefficient ERC for each patient by weighted summation i , and the generated risk coefficient ERC for each patient i Compared with the pre-set aggravation risk factor threshold [ERC1 , ERC 2 ] intervals to assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and to classify each patient based on the assessment results. The specific analysis is as follows:

[0036] If ERC i <ERC 1 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is low risk, and the patient is classified as a low-risk patient;

[0037] If ERC 1 ≤ERC i ≤ERC 2 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is medium risk, and the patient is classified as a medium-risk patient;

[0038] If ERC i >ERC 2 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is high, and the patient is classified as a high-risk patient.

[0039] Preferably, according to the classification results of all patients, a personalized follow-up plan for low risk, medium risk and high risk is formulated and implemented, as follows:

[0040] For low-risk patients, develop and implement a low-intensity follow-up plan and provide basic health guidance;

[0041] For patients at medium risk, develop and implement a moderate intensity follow-up plan and provide targeted health guidance;

[0042] For high-risk patients, develop and implement intensive follow-up plans, formulate emergency treatment plans, and provide comprehensive health guidance and preventive measures.

[0043] Preferably, the dynamic information of the follow-up plan during its implementation is obtained, and after being obtained, it is analyzed to evaluate the implementation of the follow-up plan, and the follow-up plan is dynamically adjusted according to the evaluation results, which specifically includes the following steps:

[0044] Obtain dynamic information during the implementation of the follow-up plan, including physiological parameter records and treatment compliance information of all patients;

[0045] Pre-process the physiological parameter records and treatment compliance information of all patients;

[0046] Extracting key physiological data from the preprocessed physiological parameter record information of each patient and medication record data from the treatment compliance information, and analyzing them after extraction to generate a physiological parameter fluctuation index and a treatment compliance coefficient for each patient respectively;

[0047] The generated physiological parameter fluctuation index and treatment compliance coefficient of each patient are used to construct an execution evaluation model, and the execution evaluation coefficient of each patient is generated. The generated execution evaluation coefficient of each patient is compared with the pre-set execution evaluation coefficient threshold range to evaluate the implementation of the follow-up plan of each patient, and dynamically adjust the follow-up plan according to the evaluation results.

[0048] Preferably, the logic for obtaining the physiological parameter fluctuation index and treatment compliance coefficient of each patient is as follows:

[0049] Extract key physiological data from the pre-processed physiological parameter record information of each patient, including the blood oxygen saturation and corresponding time points of each patient at different times during the implementation of the follow-up plan, and use the function SPO according to the time series i (t), t is the time point, SPO i (t) represents the blood oxygen saturation of the ith patient at time t during the implementation of the follow-up plan, and the time period is defined as [t1, t2];

[0050] Perform Fourier transform on the blood oxygen saturation of the i-th patient at time t within a period of time, according to the formula:

[0051]

[0052] In the formula, F(SPO i (t)) is the blood oxygen saturation SPO of the i-th patient at time t within a period of time i (frequency component of t, t is the time variable, j is the frequency variable, and d is the imaginary unit;

[0053] Take the amplitude of the Fourier transform result of the blood oxygen saturation of the ith patient at time t within a period of time, that is, the absolute value |F(SPO i (t))|, represents the amplitude of the blood oxygen saturation of the i-th patient at time t within a period of time at different frequencies;

[0054] Calculate the physiological parameter fluctuation index of each patient. The specific calculation formula is as follows:

[0055]

[0056] Where, PPFI i is the physiological parameter fluctuation index of the i-th patient;

[0057] Extract the medication record data from the pre-processed treatment compliance information of each patient, including the total number of times each patient actually took medication at different times during a period of time during the implementation of the follow-up plan, and mark the total number of times each patient actually took medication during a period of time during the implementation of the follow-up plan as NA i , NA i It represents the total number of times the ith patient actually took medication during a period of time during the implementation of the follow-up plan;

[0058] Obtain the total number of medications that each patient needs during the implementation of the follow-up plan, and mark the total number of medications that each patient needs during the implementation of the follow-up plan as NT i , NT i It represents the total number of medications that the i-th patient needs to take during a period of time during the implementation of the follow-up plan;

[0059] Calculate the treatment compliance coefficient of each patient. The specific calculation formula is as follows:

[0060]

[0061] Where, TAC i is the treatment compliance coefficient of the ith patient.

[0062] Preferably, the generated physiological parameter fluctuation index PPFI for each patient is i and treatment adherence coefficient TAC i Construct an execution evaluation model and generate the execution evaluation coefficient EEC of each patient through weighted summation i , and the execution evaluation coefficient EEC of each patient generated i The execution evaluation coefficient threshold interval EEC is set 1 , EEC 2 ] to compare and evaluate the implementation of the follow-up plan for each patient, and dynamically adjust the follow-up plan based on the evaluation results. The specific analysis is as follows:

[0063] If EEC i <EEC 1 , the patient's follow-up plan implementation is poor, and it is necessary to significantly increase the follow-up frequency of the follow-up plan, strengthen monitoring measures, and adjust the treatment plan;

[0064] If EEC 1 ≤EEC i ≤EEC 2 The follow-up plan for this patient is generally implemented, and it is necessary to slightly increase the frequency of follow-up and strengthen monitoring measures, and adjust the treatment plan as needed;

[0065] If EECi >EEC 2 The follow-up plan for this patient is being implemented well. The follow-up frequency of the current follow-up plan will be maintained and no adjustments will be made to the follow-up plan.

[0066] Preferably, an otolaryngology patient management and follow-up system comprises a patient file management module, a peak risk assessment module, a personalized follow-up plan module, a dynamic follow-up assessment module and an intelligent follow-up report module;

[0067] Patient file management module, which obtains the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans, establishes the patient's personal file, and enters his symptom data and allergy history into the system;

[0068] Peak risk assessment module, during the peak pollen season, obtains and analyzes the symptom records of all patients and the environmental pollen concentration information, assesses the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and classifies each patient according to the assessment results;

[0069] The personalized follow-up plan module develops and implements personalized follow-up plans for low-risk, medium-risk, and high-risk patients based on the classification results of all patients;

[0070] Dynamic follow-up evaluation module, which obtains dynamic information of the follow-up plan during its implementation, analyzes it after acquisition, evaluates the implementation of the follow-up plan, and dynamically adjusts the follow-up plan based on the evaluation results;

[0071] The intelligent follow-up report module generates follow-up reports regularly and sends them to doctors and patients, while providing patients with long-term health management advice.

[0072] In the above technical solution, the technical effects and advantages provided by the present invention are:

[0073] 1. The present invention obtains the patient's physiological parameter record information and treatment compliance information in real time, and uses advanced algorithms such as Fourier transform and weighted summation to dynamically generate and adjust the follow-up plan to ensure that the follow-up plan can respond to changes in pollen concentration in a timely manner. During the peak pollen season, the patient's allergic symptoms fluctuate frequently due to the rapid changes in pollen concentration in the environment. The present invention can accurately evaluate and optimize the follow-up plan through real-time data monitoring and dynamic adjustment mechanisms, ensuring that patients can receive follow-up guidance and treatment adjustments in a timely manner when the pollen concentration changes suddenly, effectively reducing the fluctuation and aggravation of allergic symptoms, and ensuring disease control and overall treatment effects.

[0074] 2. The present invention develops and implements personalized follow-up plans for low risk, medium risk and high risk according to the patient classification results, so that each patient can receive follow-up management that best suits their health condition. During the peak pollen period, the existing technology failed to respond to changes in pollen concentration in a timely manner because the patient's actual condition did not match the established follow-up plan. The present invention assesses the risk level of each patient's allergic symptoms aggravated by changes in pollen concentration, provides targeted follow-up frequency and health guidance, avoids excessive or insufficient medical intervention, ensures that high, medium and low risk patients receive corresponding medical support and preventive measures, and effectively improves patients' treatment compliance and satisfaction.

[0075] 3. The present invention obtains and analyzes the patient's symptom record information and environmental pollen concentration information, evaluates the risk level of each patient's allergic symptoms aggravated by changes in pollen concentration, and classifies them accordingly, so as to identify high-risk patients in advance and take preventive measures in time. The existing technology is unable to monitor and analyze pollen concentration data in real time, and is unable to generate personalized follow-up plans, resulting in patients failing to receive timely follow-up guidance and treatment adjustments when the pollen concentration changes suddenly. The present invention utilizes the immune response fluctuation index and the pollen concentration variation coefficient to construct an aggravation risk assessment model, which achieves a rapid response to sudden changes in pollen concentration, significantly reduces the pain and medical burden of patients during peak periods, avoids worsening of the disease and delays in treatment, and improves the effectiveness of medical services and management efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0076] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present invention. For ordinary technicians in this field, other drawings can also be obtained based on these drawings.

[0077] Figure 1 The present invention is a flowchart of an otolaryngology patient management and follow-up system and method.

[0078] Figure 2 The module diagram of an otolaryngology patient management and follow-up system and method of the present invention is shown. DETAILED DESCRIPTION

[0079] Example embodiments will now be described more fully with reference to the accompanying drawings. However, example embodiments can be implemented in a variety of forms and should not be construed as limited to the examples set forth herein; rather, these example embodiments are provided so that the description of the present disclosure will be more comprehensive and complete, and the concept of the example embodiments will be fully conveyed to those skilled in the art.

[0080] The present invention provides Figure 1A method for follow-up management of ENT patients is shown, which specifically includes the following steps:

[0081] Obtain the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans, establish the patient's personal file, and enter their symptom data and allergy history into the system;

[0082] There are many ways to obtain a patient's basic information and related medical data. First, when a patient first visits a doctor, they can fill out an electronic form or enter basic information (such as name, gender, date of birth, contact information, etc.) and medical records on a tablet device in the clinic. During the diagnosis and treatment process, doctors can use the electronic health record (EHR) system to record the patient's allergy symptom description, diagnosis results, and treatment plan in real time. The patient's historical medical record data can be imported from the hospital's database by connecting to the interface of the hospital information system (HIS). In addition, the symptoms and allergic reaction information recorded by the patient in daily life can be obtained by connecting to the patient's mobile health application. These data are transmitted through a secure network protocol to ensure privacy and data security.

[0083] After obtaining the patient's basic information and relevant medical data, the system automatically generates a personal file for each patient. Through the software system, the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans are integrated into an electronic file. The file creation process includes data standardization and format conversion to ensure that all data is stored in a unified format. The system generates a unique patient ID to ensure accurate data matching and subsequent management. Patient files can be viewed and edited through the system's user interface, and doctors and authorized medical staff can add or update file content as needed. In addition, the system can set access rights to ensure that only authorized personnel can view and edit sensitive information, thereby protecting patient privacy.

[0084] After establishing a patient profile, the patient's symptom data and allergy history need to be entered into the system in detail. Doctors can use portable devices (such as tablets or laptops) to record the patient's symptoms and allergy history in real time during the diagnosis and treatment process, or convert paper records into electronic data for entry through the software system after the diagnosis and treatment. Patients can also record their daily symptoms and allergic reactions through mobile applications and synchronize these data into the system. The system uses natural language processing (NLP) technology to automatically parse and structure the input data to ensure the accuracy and completeness of symptom descriptions and allergy history. The entered data will be stored in the patient's personal profile and associated with other medical data to facilitate comprehensive analysis and evaluation by doctors in subsequent follow-up visits. Data verification and error detection functions during the entry process can help reduce manual entry errors and improve data quality and reliability.

[0085] During the peak pollen season, we obtain symptom records of all patients and information on environmental pollen concentrations, analyze the information, assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and classify each patient based on the assessment results;

[0086] In this embodiment, during the pollen peak period, the symptom record information and environmental pollen concentration information of all patients are obtained, and after being obtained, they are analyzed to evaluate the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and each patient is classified according to the evaluation results, which specifically includes the following steps:

[0087] During the peak pollen season, all patients were provided with symptom records and information on ambient pollen concentrations;

[0088] There are many ways to determine the peak pollen period. First, you can use the pollen monitoring data provided by meteorological agencies, which usually include daily pollen concentration levels and historical pollen concentration trends. The software system can connect to the database of the meteorological agency to obtain pollen concentration data in real time and identify the peak pollen period by analyzing historical data. Specifically, the system can set a pollen concentration threshold. When the pollen concentration level exceeds this threshold for many consecutive days, the system will automatically determine that it has entered the peak pollen period. In addition, the system can also analyze years of pollen data through machine learning algorithms to predict future peak pollen periods. In these ways, the system can accurately identify and mark the peak pollen period to ensure that specific follow-up management processes are initiated during this period.

[0089] Preprocessing of all patients’ symptom records and environmental pollen concentration information;

[0090] Acquiring all patients’ symptom records and environmental pollen concentration information can be achieved in a variety of ways. For patients’ symptom records, the software system can collect them through patients’ mobile applications, which allow patients to record their symptoms daily, such as nasal congestion, sneezing, runny nose, etc. The system can set daily reminders to prompt patients to record their symptoms on time, and automatically synchronize these data to a central database. For environmental pollen concentration information, the system can obtain pollen concentration data in real time by connecting to the API interface of a weather monitoring station or a third-party pollen monitoring service. These data include daily or even hourly pollen concentration levels, and can be segmented according to geographic location to obtain specific pollen concentration conditions in the patient’s area. All acquired data will be encrypted for transmission to ensure patient privacy and data security, and then stored on a secure server for subsequent analysis and processing by the system. In these ways, the system can continuously and accurately collect and integrate patient symptom records and environmental pollen concentration data, providing the necessary basic information for follow-up management.

[0091] Extracting the immune response data from the pre-processed symptom record information of each patient and the pollen concentration data from the environmental pollen concentration information, and analyzing them after extraction to generate the immune response fluctuation index and pollen concentration variation coefficient of each patient respectively;

[0092] The generated immune response fluctuation index and pollen concentration variation coefficient of each patient are used to construct an aggravation risk assessment model to generate an aggravation risk coefficient for each patient. The generated aggravation risk coefficient for each patient is compared with the pre-set aggravation risk coefficient threshold range to evaluate the risk level of each patient's allergic symptoms aggravated by changes in pollen concentration, and each patient is classified according to the evaluation results.

[0093] The pre-set threshold intervals of the risk factor for aggravation can be determined in a variety of ways. First, these thresholds can be determined by using historical patient data and clinical research results, and by using software systems to perform data analysis and machine learning modeling. Specifically, the system can collect a large amount of historical data, including patient symptom records, pollen concentration data, immune response fluctuation index, and actual allergy aggravation events. Through statistical analysis, the system can identify characteristic parameters of different risk levels, such as the distribution range of the immune response fluctuation index and the coefficient of variation of pollen concentration for patients with aggravated symptoms during the peak pollen period. Then, the system can use cluster analysis or classification algorithms (such as K-means clustering, logistic regression, support vector machines, etc.) to train these data, establish a risk assessment model, and determine the corresponding risk factor threshold intervals. In order to improve the accuracy and reliability of the model, the system can also perform cross-validation and parameter optimization. Finally, the system will set the threshold intervals of three risk levels of high, medium, and low according to the output results of the model to ensure that these intervals can accurately reflect the risk level of aggravation of different patients due to changes in pollen concentration. This process is accomplished through automated data analysis and machine learning algorithms, which can dynamically adjust and optimize threshold intervals to adapt to different patient groups and changing environmental conditions.

[0094] In this embodiment, the logic for obtaining the immune response fluctuation index and pollen concentration variation coefficient of each patient is as follows:

[0095] Extract the immune response data from the pre-processed symptom record information of each patient, including the immunoglobulin level values ​​and corresponding time points of each patient at different times over a period of time, and use the function MYQDB according to the time series i (T) represents the time point, MYQDB i (T) represents the immunoglobulin level of the i-th patient at time T in a period of time, i = 1, 2, 3, ..., k, k is a positive integer, and the time period is defined as [T1, T2];

[0096] The software system can extract immune response data from the patient's electronic health record (EHR) and symptom logs in mobile applications. The specific method is that first, the software system will connect to the hospital information system (HIS) or other health management platform to obtain the patient's immunoglobulin test results, which usually record the patient's immunoglobulin level value at a specific time point. Secondly, the software system can collect the symptom logs entered by patients on a daily basis through the health applications used by patients. These logs can include manually entered immunoglobulin level data or data automatically uploaded through home testing devices (such as portable immunoassay analyzers). The system automatically preprocesses the data, matches the immunoglobulin level values ​​at different times with the corresponding time points, and standardizes them into a unified format to ensure the consistency and accuracy of the data. All extracted data will be centrally stored in a cloud database for subsequent analysis, and the software system will also perform data verification to eliminate outliers and noise to ensure the reliability of the data. This process is achieved through automated data acquisition and preprocessing functions to ensure efficient and accurate extraction of the required immune response data.

[0097] Perform Fourier transform on the immunoglobulin level of the i-th patient at time T within a period of time, according to the formula:

[0098]

[0099] In the formula, F(MYQDB i (T)) is the immunoglobulin level value MYQDB at time T in the immune response data of the i-th patient with worsening symptoms i (T) frequency component, T is the time variable, f is the frequency variable, and z is the imaginary unit;

[0100] Fourier transform is a mathematical tool used to convert time domain signals into frequency domain signals. It can decompose the components of different frequencies in the signal and the corresponding amplitudes. The purpose of Fourier transforming the immunoglobulin level values ​​of the i-th patient at time T over a period of time is to analyze the frequency characteristics of the patient's immune response. The data of immunoglobulin levels changing over time may contain periodic changes and noise. The frequency components of these changes can be extracted through Fourier transform, so as to better understand and quantify the fluctuations of the patient's immune response. The frequency variable f represents the frequency of different frequency components in the signal, reflecting the speed of signal changes; the imaginary unit z is used to represent the phase information in the complex domain, which helps to describe the amplitude and phase relationship of the signal. The advantage of Fourier transform is that it can decompose complex time series data into simple sine waves and cosine waves, which is convenient for spectrum analysis, thereby identifying the main frequency components of changes in immunoglobulin levels. This is very useful for detecting periodic changes, identifying abnormal fluctuations and noise filtering. The software system can perform automated Fourier transform calculations, quickly analyze data from large numbers of patients, and generate frequency component maps to help doctors understand the dynamic characteristics of patients' immune responses, and more accurately assess the risk level of allergic symptoms exacerbated by changes in pollen concentrations.

[0101] The amplitude of the Fourier transform result after taking the immunoglobulin level value of the i-th patient at time T within a period of time, that is, the absolute value |F(MYQDB i (T))], which represents the amplitude of the immunoglobulin level value of the i-th patient at time T in a period of time at different frequencies;

[0102] After taking the immunoglobulin level value of the ith patient at time T within a period of time and performing Fourier transform, the result is a series of complex numbers, which represent the amplitude and phase of the signal at different frequencies. The amplitude of the Fourier transform, that is, the absolute value, represents the amplitude of these signals at different frequencies. Specifically, the amplitude is the modulus of the complex number, which reflects the energy intensity of the signal at the frequency component. By calculating the amplitude of the immunoglobulin level value of the ith patient in a specific period of time, the fluctuation amplitude of his immune response at different frequencies can be quantified. This amplitude information is important for understanding the dynamic changes of the patient's immune system, because high-frequency components may indicate rapid fluctuations in immune responses, while low-frequency components may reflect long-term trends and chronic changes. Through the software system, the amplitude information after Fourier transform can be automatically extracted to generate spectrograms, which show the amplitude distribution of immunoglobulin levels at different frequencies. Doctors can use these spectrograms to identify the main frequency components in the immune response, understand the immune fluctuation characteristics of patients, and more accurately assess the risk of their allergic symptoms being aggravated by changes in pollen concentration. The software system's automated processing and visualization capabilities make this complex mathematical analysis process intuitive and easy to understand, providing strong data support for clinical decision-making.

[0103] Calculate the immune response fluctuation index of each patient. The specific calculation formula is as follows:

[0104]

[0105] Where IRFI i is the immune response fluctuation index of the i-th patient;

[0106] The immune response fluctuation index of the i-th patient is an indicator to measure the intensity of fluctuation of its immunoglobulin level in a specific time period. It is calculated by Fourier transforming the immunoglobulin level value, extracting its amplitude at different frequencies, and then integrating these amplitudes over the entire time period. i The size of the IRFI reflects the sensitivity of the patient's immune system to environmental changes. i The IRFI index indicates that the patient's immunoglobulin levels fluctuate frequently and dramatically over a period of time, indicating that his immune system is more sensitive and intense to allergens such as pollen. Therefore, the patient is at a higher risk of having allergy symptoms aggravated by changes in pollen concentration. i The IRFI index indicates that the immunoglobulin level is relatively stable with less fluctuation, indicating that the patient's reaction to allergens is relatively weak and the risk of aggravation of allergic symptoms due to changes in pollen concentration is low. iCombined with the pollen concentration variation coefficient, it is possible to more accurately assess each patient's risk level of worsening allergic symptoms during the pollen peak period, and classify them into high, medium, and low risk accordingly, providing a scientific basis for personalized follow-up plans and treatment programs.

[0107] Extract pollen concentration data from the preprocessed environmental pollen concentration information, including the average pollen concentration of each patient's activity area at different times within a period of time, and calibrate the average pollen concentration of each patient's activity area at different times within a period of time as represents the average pollen concentration of the activity area of ​​the ith patient at time m within a period of time, m = 1, 2, 3, ..., g, where g is a positive integer;

[0108] Pollen concentration data can be obtained from environmental monitoring agencies, weather stations or third-party pollen monitoring services through the software system. These data usually include pollen concentration levels at different times. First, the software system can be connected to the API interface of these data sources to obtain pollen concentration information in each patient's activity area in real time or at a fixed time. The specific method is that the system extracts pollen concentration data in the corresponding area based on the patient's geographic location data, and records the average pollen concentration value at different times within a specific time period. The system will preprocess the raw data, including removing outliers and filling missing data to ensure the accuracy and consistency of the data. The preprocessed data will be stored in the system's database, and the system will calculate the average pollen concentration at different times in each patient's activity area according to the set time interval (such as hourly or daily). In these ways, the software system can efficiently and accurately extract and process environmental pollen concentration information, providing a reliable data basis for subsequent analysis and evaluation.

[0109] Calculate the mean and standard deviation of the average pollen concentration in the activity area of ​​each patient over a period of time according to the formula:

[0110]

[0111] In the formula, is the average pollen concentration of the i-th patient’s activity area over a period of time, is the standard deviation of the average pollen concentration in the activity area of ​​the ith patient over a period of time;

[0112] Calculate the coefficient of variation of pollen concentration for each patient. The specific calculation formula is as follows:

[0113]

[0114] Where, PCVC i is the coefficient of variation of pollen concentration of the ith patient.

[0115] The coefficient of variation of pollen concentration PCVC of the i-th patient i It is an indicator to measure the intensity of fluctuations in pollen concentration within its activity area within a specific period of time. i It is calculated by calculating the ratio of the standard deviation of the average pollen concentration at different times in the patient's activity area during the time period to the average value, reflecting the volatility of pollen concentration. i The index indicates that the pollen concentration in the patient's activity area changes dramatically over time, indicating that the patient is exposed to significantly different pollen concentration levels at different times, making his or her allergic symptoms more likely to be aggravated by changes in pollen concentration. i The PCVC index indicates that the pollen concentration is relatively stable with less fluctuation, indicating that the patient's allergic symptoms are less affected by changes in pollen concentration, and therefore the risk of aggravation of allergic symptoms is lower. i , can more accurately determine the possibility of worsening allergic symptoms during the peak pollen period, thereby providing a scientific basis for the classification of high, medium and low risk levels, and formulate more personalized follow-up plans and treatment strategies based on the classification results, thereby improving patients' treatment outcomes and quality of life.

[0116] In this embodiment, the immune response fluctuation index IRFI of each patient is generated i and pollen concentration variation coefficient PCVC i Construct an exacerbation risk assessment model and generate the exacerbation risk coefficient ERC for each patient by weighted summation i , and the generated risk coefficient ERC for each patient i Compared with the pre-set aggravation risk factor threshold [ERC 1 , ERC 2 ] intervals to assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and to classify each patient based on the assessment results. The specific analysis is as follows:

[0117] If ERC i <ERC 1, the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is low, and the patient is classified as a low-risk patient, which means that the combined result of the patient's immune response fluctuation index and the pollen concentration variation coefficient is low, indicating that the patient's immune system is less sensitive to changes in pollen concentration, and the risk of aggravation of his allergic symptoms due to changes in pollen concentration during the peak pollen season is low. Specifically, low-risk patients have relatively stable immune responses, and the pollen concentration in their environment does not vary much. Such patients usually do not experience severe aggravation of allergic symptoms due to fluctuations in pollen concentration. Therefore, more conventional measures can be used in follow-up management and treatment plans, and no special intervention is required. This not only reduces the use of medical resources, but also reduces the psychological burden of patients, ensuring that they can maintain normal life and work during the peak pollen season;

[0118] If ERC 1 ≤ERC i ≤ERC 2 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is medium risk, and the patient is classified as a medium-risk patient, which indicates that the patient's immune response fluctuation index and pollen concentration variation coefficient are at a medium level, which means that the patient's immune system is sensitive to changes in pollen concentration. The risk of aggravation of allergic symptoms due to changes in pollen concentration during the peak pollen season is high. For medium-risk patients, although their risk of aggravation of allergic symptoms is not as significant as that of high-risk patients, they still need to be properly monitored and managed. The follow-up plan should include regular examinations and timely symptom records. At the same time, it may be necessary to adjust the medication regimen to cope with symptom fluctuations. This moderate intervention can help patients effectively control allergic symptoms during the peak pollen season and avoid worsening of symptoms, thereby improving the patient's quality of life and treatment effect;

[0119] If ERC i >ERC 2 The patient's risk level for aggravation of allergic symptoms due to changes in pollen concentration is high, and the patient is classified as a high-risk patient, which means that the combined results of the patient's immune response fluctuation index and pollen concentration variation coefficient are high, indicating that the patient's immune system is very sensitive to changes in pollen concentration, and the risk of aggravation of his allergic symptoms due to changes in pollen concentration during the peak pollen season is extremely high. High-risk patients require special attention and management. Follow-up plans should include frequent symptom monitoring, detailed allergen exposure records, and personalized treatment adjustment plans. Medication may need to be strengthened, and even preventive measures such as reducing outdoor activities or using air purification equipment may be taken when necessary. Such active management measures can significantly reduce the health risks of patients caused by worsening allergic symptoms, prevent the occurrence of acute allergic reactions, and improve the safety and comfort of patients during the peak pollen season. At the same time, it provides doctors with sufficient data support to optimize treatment plans.

[0120] In order to construct the aggravation risk assessment model and generate the aggravation risk coefficient of each patient by weighted summation, it is first necessary to collect and process the immune response fluctuation index and pollen concentration variation coefficient of each patient. Next, the immune response fluctuation index IRFI of each patient is calculated by weighted summation. i and pollen concentration variation coefficient PCVC i Combined generation of aggravated risk factor ERC i The specific method is that the software system uses predetermined weight coefficients α and β, which are set based on clinical data and expert experience to reflect the relative importance of immune response fluctuations and changes in pollen concentration to the risk of aggravated allergic symptoms. i =α*IRFI i +β*PCVC i The system automatically calculates the exacerbation risk coefficient ERC for each patient i The weight coefficients α and β can be adjusted according to the specific characteristics of the patient population to improve the accuracy and applicability of the model. i It reflects the patient's comprehensive risk of aggravated allergic symptoms due to changes in pollen concentration. Through this automated calculation process, the software system can efficiently and accurately generate each patient's aggravation risk coefficient, providing a scientific basis for further risk level assessment and personalized follow-up management.

[0121] According to the classification results of all patients, develop and implement personalized follow-up plans for low risk, medium risk and high risk respectively;

[0122] In this embodiment, according to the classification results of all patients, personalized follow-up plans for low risk, medium risk and high risk are formulated and implemented respectively, as follows:

[0123] For low-risk patients, develop and implement a low-intensity follow-up plan to regularly monitor the patient's symptom changes and health status and provide basic health guidance;

[0124] The exacerbation risk factor of low-risk patients is lower than the preset low-risk threshold, indicating that their immune system is less sensitive to changes in pollen concentrations, and the risk of allergic symptoms being aggravated by changes in pollen concentrations during the peak pollen season is low. For such patients, the software system will automatically generate a low-intensity follow-up plan, including monthly symptom records and brief follow-up calls or online consultations. For example, the system will send an online questionnaire to patients every month to ask about changes in their allergy symptoms and arrange monthly telephone follow-ups. Doctors or nurses will understand the patient's health status over the phone and provide general health guidance, such as how to reduce pollen exposure and keep the room clean. This follow-up method helps patients effectively manage symptoms during the peak pollen season through regular monitoring and guidance, avoid excessive medical intervention, and ensure that patients receive basic health support.

[0125] For medium-risk patients, develop and implement a moderate-intensity follow-up plan to monitor the patient's symptom changes and health status more frequently, adjust treatment plans when necessary, and provide targeted health guidance;

[0126] The exacerbation risk factor of medium-risk patients is within the preset medium-risk threshold range, which means that their immune system is moderately sensitive to changes in pollen concentration, and the risk of allergic symptoms being aggravated due to changes in pollen concentration during the peak pollen season is high. For such patients, the software system will generate a moderate-intensity follow-up plan, including detailed symptom records every two weeks and regular doctor visits or remote consultations. For example, the system will remind patients to fill out a detailed symptom log every two weeks, record daily symptom changes, and arrange a remote video consultation every two weeks. The doctor will understand the patient's symptom changes through the video, adjust the treatment plan if necessary, such as replacing or adding anti-allergic drugs, and provide personalized health guidance, such as using air purifiers, avoiding going out during peak outdoor activities, etc. Through more frequent monitoring and intervention, ensure that medium-risk patients are managed in a timely and effective manner during the peak pollen season.

[0127] For high-risk patients, develop and implement a high-intensity follow-up plan to frequently monitor the patient's symptom changes and health status, respond quickly to worsening symptoms, develop emergency treatment plans, and provide comprehensive health guidance and preventive measures;

[0128] The exacerbation risk factor of high-risk patients is higher than the preset high-risk threshold, indicating that their immune system is very sensitive to changes in pollen concentration, and the risk of allergic symptoms being aggravated due to changes in pollen concentration during the peak pollen season is extremely high. For such patients, the software system will generate a high-intensity follow-up plan, including weekly or more frequent symptom records and frequent doctor visits or remote video consultations. For example, the system will remind patients to fill out symptom logs every week and arrange weekly face-to-face or remote video consultations. Doctors will quickly adjust treatment plans based on the latest symptom changes of patients, and formulate emergency treatment plans when necessary, such as equipping emergency drugs and equipment, recommending reduced outdoor activities, and using high-efficiency air filtration devices. Through frequent monitoring and timely medical intervention, it is ensured that high-risk patients can quickly respond to symptom aggravation during the peak pollen season, reduce health risks, and improve quality of life.

[0129] Obtain dynamic information during the implementation of the follow-up plan, analyze it after acquisition, evaluate the implementation of the follow-up plan, and dynamically adjust the follow-up plan based on the evaluation results;

[0130] In this embodiment, dynamic information of the follow-up plan during its implementation is obtained, and after being obtained, it is analyzed to evaluate the implementation of the follow-up plan, and the follow-up plan is dynamically adjusted according to the evaluation results, which specifically includes the following steps:

[0131] Obtain dynamic information during the implementation of the follow-up plan, including physiological parameter records and treatment compliance information of all patients;

[0132] Obtaining dynamic information during the implementation of the follow-up plan, including physiological parameter recording information and treatment compliance information of all patients, can be achieved through multiple software platforms and devices. First, patients can use portable physiological monitoring devices (such as smart bracelets, smart watches or portable physiological parameter monitors) to record their physiological parameter data in real time. These devices connect via Bluetooth or Wi-Fi to automatically synchronize the data to the patient's smartphone application. The data collected by the smartphone application include key physiological indicators such as heart rate, respiratory rate, and blood oxygen saturation. At the same time, the software system can also connect to the hospital information system (HIS) or electronic health record system (EHR) to obtain patient treatment compliance data recorded by doctors, such as the use of prescribed drugs and patients' medication records. Patients can also manually enter their medication time and dosage through the mobile application, and the system will automatically record this information. All data are transmitted through a secure network protocol to ensure privacy and data security, and are centrally stored in a cloud database. The software system will integrate and preprocess the collected physiological parameter recording information and treatment compliance information for subsequent analysis and evaluation. This process achieves efficient and accurate data collection and management through automated data acquisition and synchronization functions, providing reliable basic information for dynamic adjustment of follow-up plans.

[0133] Pre-process the physiological parameter records and treatment compliance information of all patients;

[0134] Preprocessing of all patients' physiological parameter recording information and treatment compliance information is to ensure the accuracy, consistency and availability of the data, thereby improving the reliability of subsequent analysis and evaluation. The preprocessing process includes multiple steps. The first is data cleaning. The software system automatically detects and removes outliers, duplicate records and noise data to ensure the accuracy of the data. For example, for heart rate data, if the recorded value at a certain time point is obviously abnormal (such as beyond a reasonable range), the system will mark and remove these data. The second is data completion. For missing data points, the system can use interpolation or prediction algorithms based on historical data to reasonably fill in the missing data points to ensure the integrity of the data. Then there is data standardization. In order to ensure the comparability of data from different devices and sources, the system will standardize the physiological parameter data and convert data of different units and ranges into a unified standard format. Finally, there is data synchronization and integration. The system will integrate data from different times and sources into a unified database and perform time alignment on the data to ensure that the timestamps of physiological parameter records and treatment compliance information are consistent. Through the above preprocessing steps, the software system can provide high-quality data and provide a reliable basis for dynamic adjustment and accurate evaluation of follow-up plans.

[0135] Extracting key physiological data from the preprocessed physiological parameter record information of each patient and medication record data from the treatment compliance information, and analyzing them after extraction to generate a physiological parameter fluctuation index and a treatment compliance coefficient for each patient respectively;

[0136] The generated physiological parameter fluctuation index and treatment compliance coefficient of each patient are used to construct an execution evaluation model, and the execution evaluation coefficient of each patient is generated. The generated execution evaluation coefficient of each patient is compared with the pre-set execution evaluation coefficient threshold range to evaluate the implementation of the follow-up plan of each patient, and dynamically adjust the follow-up plan according to the evaluation results.

[0137] The pre-set threshold intervals of the execution evaluation coefficient can be determined by analyzing a large amount of historical patient data and clinical research results. First, the software system collects and processes the physiological parameter fluctuation index and treatment compliance coefficient data of a large number of patients, including patients with different health conditions and treatment compliance levels. Through data mining and statistical analysis, the system can identify the distribution of these parameters under different follow-up effects. Specific methods include using machine learning algorithms (such as cluster analysis, logistic regression, and decision trees) to classify and regress the data to determine which parameter combinations are associated with good, medium, or poor follow-up execution. The system models these historical data and generates a distribution map of the execution evaluation coefficient. Based on these analysis results, the system can set reasonable threshold intervals, such as an execution evaluation coefficient above a certain threshold indicates that the follow-up plan is well executed, an execution coefficient in the middle interval indicates that the follow-up plan is generally executed, and a execution coefficient below a certain threshold indicates that the follow-up plan is poorly executed. These threshold intervals are repeatedly verified and optimized to ensure their scientificity and accuracy. Finally, the system will build these preset execution evaluation coefficient threshold intervals into the evaluation model to realize automated follow-up plan execution evaluation and dynamic adjustment to ensure the effectiveness and accuracy of follow-up management.

[0138] In this embodiment, the logic for obtaining the physiological parameter fluctuation index and treatment compliance coefficient of each patient is as follows:

[0139] Extract key physiological data from the pre-processed physiological parameter record information of each patient, including the blood oxygen saturation and corresponding time points of each patient at different times during the implementation of the follow-up plan, and use the function SPO according to the time series i (t), t is the time point, SPO i (t) represents the blood oxygen saturation of the ith patient at time t during the implementation of the follow-up plan, and the time period is defined as [t1, t2];

[0140] There are many ways to extract the blood oxygen saturation and corresponding time points of each patient during the implementation of the follow-up plan. First, patients can wear smart health monitoring devices, such as smart watches, smart bracelets, or portable pulse oximeters, which can continuously monitor and record the patient's blood oxygen saturation and transmit the data in real time to the patient's smartphone application via Bluetooth or Wi-Fi. The smartphone application uploads this data to the cloud database to ensure the real-time and security of the data. At the same time, the software system will integrate with the electronic health record system of the medical institution to obtain the blood oxygen saturation data recorded by the doctor during the follow-up process. After all these data are uploaded to the cloud, the software system will pre-process them, including timestamp alignment, outlier detection and processing, missing data completion, etc. Through these steps, the system can extract the blood oxygen saturation data of each patient at each time point in the specified time period and standardize it into a unified format to ensure the consistency and accuracy of the data. This process achieves efficient and accurate data extraction through automated data acquisition, synchronization, and preprocessing functions, providing a reliable basis for subsequent analysis and evaluation.

[0141] Perform Fourier transform on the blood oxygen saturation of the i-th patient at time t within a period of time, according to the formula:

[0142]

[0143] In the formula, F(SPO i (t)) is the blood oxygen saturation SPO of the i-th patient at time t within a period of time i (frequency component of t, t is the time variable, j is the frequency variable, and d is the imaginary unit;

[0144] The purpose of Fourier transforming the patient's blood oxygen saturation over a period of time is to convert the time domain signal into a frequency domain signal, thereby revealing the frequency components in the changes in blood oxygen saturation. Fourier transform can help us identify and analyze periodic changes and fluctuation patterns in blood oxygen saturation data, which is very important for understanding the patient's physiological state and detecting abnormalities. The frequency variable j represents the frequency of different frequency components in the signal, reflecting how fast the blood oxygen saturation changes over time. High-frequency components usually correspond to rapid, short-term fluctuations, such as acute physiological changes or noise, while low-frequency components correspond to slow, long-term trends, such as changes in chronic health conditions. The imaginary unit d is used to represent phase information in the complex domain, which helps describe the relationship between the amplitude and phase of the signal. In the Fourier transform, the complex form allows us to process the amplitude and phase of the signal at the same time, which is crucial for accurately describing the nature of blood oxygen saturation changes. Through the software system, the Fourier transform can be automated to perform frequency analysis on each patient's blood oxygen saturation data, thereby generating a spectrogram showing the amplitude at different frequencies. This process helps doctors and medical teams better understand the patient's physiological changes and develop more effective follow-up plans and treatment plans.

[0145] Take the amplitude of the Fourier transform result of the blood oxygen saturation of the ith patient at time t within a period of time, that is, the absolute value |F(SPO i (t))|, represents the amplitude of the blood oxygen saturation of the i-th patient at time t within a period of time at different frequencies;

[0146] After Fourier transforming the blood oxygen saturation of the ith patient at a certain time, the result is a series of complex numbers, which represent the amplitude and phase of the signal at different frequencies. The amplitude of the Fourier transform result, that is, the absolute value, reflects the energy intensity of these signals at each frequency component. Specifically, the amplitude is the modulus of the complex number, and the calculation formula is |F(SPO i (t))|, which represents the intensity of the fluctuation of blood oxygen saturation at each frequency j. By calculating these amplitudes, we can quantify the fluctuation of the patient's blood oxygen saturation. High amplitudes indicate significant fluctuations in blood oxygen saturation at a certain frequency, which may be related to specific physiological or pathological events. For example, higher-frequency components may reflect the patient's rapid breathing or instantaneous changes in blood oxygen saturation, while lower-frequency components may correspond to long-term chronic changes or basal states. Combining the amplitude of the Fourier transform with the amplitude within the time period can comprehensively analyze the fluctuation of the patient's blood oxygen saturation at different frequencies. By automatically extracting and analyzing these amplitude data through the software system, doctors can identify abnormal fluctuation patterns, further diagnose the patient's health status, and formulate personalized treatment and follow-up plans based on these analysis results, thereby improving the accuracy and effectiveness of medical services.

[0147] Calculate the physiological parameter fluctuation index of each patient. The specific calculation formula is as follows:

[0148]

[0149] Where, PPFI i is the physiological parameter fluctuation index of the i-th patient;

[0150] Physiological parameter fluctuation index PPFI of the i-th patient i It is the amplitude integral value of blood oxygen saturation at different frequencies calculated by Fourier transform. This index reflects the fluctuation intensity of the patient's physiological parameters in a specific period of time. i It means that the patient's blood oxygen saturation has significant fluctuations during the follow-up period, which may indicate that the patient's health condition is unstable or the follow-up plan is not being implemented well. For example, frequent changes in blood oxygen saturation may indicate that the patient does not strictly follow the doctor's advice, take medication or take other preventive measures on time; it may also reflect that the treatment plan has not effectively controlled the disease. On the contrary, a lower PPFI i This means that the patient's blood oxygen saturation is relatively stable, indicating that the follow-up plan is well implemented, the patient's health condition is relatively stable, and the treatment plan is effective. i , doctors can evaluate the effectiveness of follow-up plans and adjust treatment plans and follow-up measures in a timely manner to ensure that patients receive the best care and support. The software system can automatically calculate and monitor PPFI i , helping medical teams quickly identify poorly executed follow-up plans, take corresponding improvement measures, and optimize patient management processes.

[0151] Extract the medication record data from the pre-processed treatment compliance information of each patient, including the total number of times each patient actually took medication at different times during a period of time during the implementation of the follow-up plan, and mark the total number of times each patient actually took medication during a period of time during the implementation of the follow-up plan as NA i , NA i It represents the total number of times the ith patient actually took medication during a period of time during the implementation of the follow-up plan;

[0152] There are many ways to extract the total number of times each patient actually took medication at different times during the implementation of the follow-up plan. First, patients can use smart pill boxes or electronic pill bottles, which are equipped with sensors and counters that can record the time of each opening of the lid to take medication and transmit the data in real time to the patient's smartphone application via Bluetooth or Wi-Fi. The smartphone application will summarize this data and upload it to the cloud database to ensure the real-time and integrity of the data. Secondly, patients can also manually record their medication time and dosage through mobile health management applications, and the system will automatically save these records. In addition, the software system can be integrated with the hospital information system (HIS) or electronic health record system (EHR) to obtain the patient's medication information recorded by the doctor. After the data is uploaded to the cloud, the software system will perform data preprocessing, including removing duplicate records, outlier detection and processing, and timestamp alignment. Through these steps, the system can extract the total number of times each patient actually took medication in a specified time period and standardize it into a unified format to ensure the consistency and accuracy of the data. In this way, doctors and medical teams can automatically obtain and analyze patients' medication compliance data through the software system, providing reliable basic information for evaluating the implementation of the follow-up plan and adjusting the treatment plan.

[0153] Obtain the total number of medications that each patient needs during the implementation of the follow-up plan, and mark the total number of medications that each patient needs during the implementation of the follow-up plan as NT i , NT i It represents the total number of medications that the i-th patient needs to take during a period of time during the implementation of the follow-up plan;

[0154] There are many ways to extract the total number of medications that each patient needs to take during a follow-up plan. First, the software system can obtain this information from the electronic prescriptions and treatment plans issued by doctors, which usually record the type, dosage and frequency of medications that patients need to take during a specified period of time. Electronic prescription systems (e-Prescription) and hospital information systems (HIS) usually record patients' treatment plans in detail and store this data in electronic health record systems (EHR). Through integration with these systems, the software can automatically extract patients' medication data. In addition, the patient's mobile health management application can also synchronize this prescription information and generate medication reminders based on the doctor's treatment plan. The system automatically calculates the total number of medications that patients need to take during a specific period of time according to the time intervals and dosage requirements in the treatment plan. For example, if the treatment plan requires the patient to take medication three times a day and the follow-up period is 30 days, the system will automatically calculate the total number of medications that need to be taken as 90 times. All of this data is transmitted through a secure network protocol to ensure privacy and data security, and is centrally stored in a cloud database. The software system will pre-process the collected data, including time alignment and format standardization, to ensure data consistency and accuracy. This process achieves efficient and accurate extraction of medication data on demand through automated data collection and processing functions, providing a solid foundation for evaluating patients' treatment compliance and follow-up plan implementation.

[0155] Calculate the treatment compliance coefficient of each patient. The specific calculation formula is as follows:

[0156]

[0157] Where, TAC i is the treatment compliance coefficient of the ith patient.

[0158] The treatment compliance coefficient TAC of the i-th patient iIt reflects the ratio of the number of times a patient actually takes medication to the total number of times they should take medication during the follow-up period. A higher treatment compliance coefficient indicates that the patient has taken the medication prescribed by the doctor on time and in the right amount, indicating that the follow-up plan is being implemented well. Such patients usually show better treatment effects and stable physiological parameters, which means that they are more likely to manage according to the doctor's advice and effectively control their condition. On the contrary, a lower treatment compliance coefficient means that the patient has failed to strictly adhere to the treatment plan, and the actual number of medications taken is far lower than the number of medications required, indicating that the follow-up plan is not being implemented well. Such patients may not receive ideal treatment effects or may even experience worsening of their condition due to failure to take medication on time or missing medication. By evaluating the treatment compliance coefficient, doctors and medical teams can identify patients who need more attention and intervention, adjust follow-up plans and treatment plans in a timely manner, and provide more personalized and intensive follow-up management to improve patients' treatment compliance and overall health. The software system automatically calculates and monitors the treatment compliance coefficient, helping the medical team to quickly identify poorly executed follow-up plans, take corresponding improvement measures, and optimize the patient management process.

[0159] In this embodiment, the physiological parameter fluctuation index PPFI of each patient is generated i and treatment adherence coefficient TAC i Construct an execution evaluation model and generate the execution evaluation coefficient EEC of each patient through weighted summation i , and the execution evaluation coefficient EEC of each patient generated i and the pre-set execution evaluation coefficient threshold interval [EEC 1 , EEC 2 ] to compare and evaluate the implementation of the follow-up plan for each patient, and dynamically adjust the follow-up plan based on the evaluation results. The specific analysis is as follows:

[0160] If EEC i <EEC 1, the implementation of the follow-up plan for this patient is poor, the patient's symptoms are not effectively controlled or the treatment compliance is low, and it is necessary to significantly increase the follow-up frequency of the follow-up plan, strengthen monitoring measures and adjust the treatment plan. This means that the patient's physiological parameter fluctuation index is high and the treatment compliance coefficient is low, indicating that the patient's physiological state fluctuates greatly and fails to take medication on time and in the right amount, resulting in unsatisfactory implementation of the follow-up plan. Specifically, the patient's health condition may deteriorate or fail to improve significantly during the follow-up period, and the treatment effect is poor. Such situations pose potential risks to the patient's health and may aggravate the condition or cause complications. Therefore, it is necessary to increase the follow-up frequency, such as once a week or more frequently, and strengthen monitoring measures, such as real-time monitoring of physiological parameters and medication. At the same time, doctors need to adjust the treatment plan based on the latest physiological and compliance data to more effectively control the condition and improve the patient's health. This can timely detect and respond to health problems, prevent further deterioration of the condition, and ensure the health and safety of patients;

[0161] If EEC 1 ≤EEC i ≤EEC 2 , the implementation of the follow-up plan for this patient is average, and the symptom improvement and treatment compliance need to be improved. It is necessary to slightly increase the follow-up frequency of the follow-up plan and strengthen monitoring measures, and adjust the treatment plan as needed. This means that the patient's physiological parameter fluctuation index and treatment compliance coefficient are both at a medium level, indicating that the patient's physiological state and medication compliance are relatively stable, but there is still room for improvement. The patient may have some symptom improvement during the follow-up period, but the overall health condition is still not optimal. Such situations have a certain impact on the patient's health and may cause recurrence or slow improvement of the disease. Therefore, it is necessary to moderately increase the follow-up frequency, such as once every two weeks, and strengthen monitoring measures, such as more frequent checks of physiological parameters and medication records. Doctors should adjust the treatment plan in a timely manner according to the patient's latest data to further improve the treatment effect and patient compliance. Through such adjustments, it is possible to better track the patient's condition changes, conduct medical interventions in a timely manner, and promote the patient's recovery and health improvement;

[0162] If EEC i >EEC 2The implementation of the follow-up plan for this patient is good, the patient's symptoms have improved significantly and the treatment compliance is high. The follow-up frequency of the current follow-up plan is maintained and no adjustment is made to the follow-up plan. This means that the patient's physiological parameter fluctuation index is low and the treatment compliance coefficient is high, indicating that the patient's physiological state is stable and he strictly follows the doctor's medication instructions. The implementation of the follow-up plan is good. The patient's symptoms have improved significantly during the follow-up period, and his health condition has improved significantly. Such conditions have a positive impact on the patient's health, help to continuously control the disease and prevent recurrence. Therefore, the current follow-up plan frequency can be maintained, such as once a month, and the patient's physiological parameters and medication can continue to be monitored. The doctor only needs to check the data regularly to ensure that the patient continues to be treated according to the established plan without making major adjustments. This method can effectively consolidate the treatment effect, help patients maintain a good health state, reduce excessive medical intervention, and improve the patient's quality of life and satisfaction.

[0163] Generate follow-up reports regularly and send them to doctors and patients, while providing patients with long-term health management advice.

[0164] In order to regularly generate and send follow-up reports to doctors and patients, the software system first regularly summarizes and analyzes all collected patient physiological parameter record information and treatment compliance information. These data include key physiological indicators such as blood oxygen saturation, heart rate, respiratory rate, as well as the actual number of medications and the total number of medications required. Through automated data processing and analysis algorithms, the system generates detailed follow-up reports, which include the patient's physiological parameter fluctuation index, treatment compliance coefficient, physiological parameter trend chart, medication compliance chart, and health status assessment during the follow-up period. After the report is generated, the system sends the report to doctors and patients via secure encrypted email or an integrated patient management platform. Doctors can view detailed reports, conduct condition assessments, and record feedback through the platform. At the same time, the system will also generate personalized long-term health management recommendations for patients based on the analysis results, including diet, exercise, medication management, and daily care. Patients can access these recommendations through mobile applications or online platforms, receive health reminders and guidance from the system, and achieve full health management. This process ensures efficient, accurate, and secure report generation and delivery, provides reliable decision support for doctors, and helps patients continuously improve their health.

[0165] like Figure 2 An ENT patient management and follow-up system is shown, comprising a patient file management module, a peak risk assessment module, a personalized follow-up plan module, a dynamic follow-up assessment module and an intelligent follow-up report module;

[0166] Patient file management module, which obtains the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans, establishes the patient's personal file, and enters his symptom data and allergy history into the system;

[0167] Peak risk assessment module, during the peak pollen season, obtains and analyzes the symptom records of all patients and the environmental pollen concentration information, assesses the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and classifies each patient according to the assessment results;

[0168] The personalized follow-up plan module develops and implements personalized follow-up plans for low-risk, medium-risk, and high-risk patients based on the classification results of all patients;

[0169] Dynamic follow-up evaluation module, which obtains dynamic information of the follow-up plan during its implementation, analyzes it after acquisition, evaluates the implementation of the follow-up plan, and dynamically adjusts the follow-up plan based on the evaluation results;

[0170] The intelligent follow-up report module generates follow-up reports regularly and sends them to doctors and patients, while providing patients with long-term health management advice.

[0171] The above formulas are all dimensionless and numerical calculations. The formula is a formula for the most recent real situation obtained by collecting a large amount of data and performing software simulation. The preset parameters in the formula are set by technicians in this field according to actual conditions.

[0172] The above embodiments can be implemented in whole or in part by software, hardware, firmware or any other combination. When implemented using software, the above embodiments can be implemented in whole or in part in the form of a computer program product. The computer program product includes one or more computer instructions or computer programs. When the computer instructions or computer programs are loaded or executed on a computer, the process or function described in the embodiment of the present application is generated in whole or in part. The computer can be a general-purpose computer, a special-purpose computer, a computer network, or other programmable device. The computer instructions can be stored in a computer-readable storage medium, or transmitted from one computer-readable storage medium to another computer-readable storage medium. For example, the computer instructions can be transmitted from one website site, computer, server or data center to another website site, computer, server or data center by wired or wireless (e.g., infrared, wireless, microwave, etc.). The computer-readable storage medium can be any available medium that a computer can access or a data storage device such as a server or data center containing one or more available media sets. The available medium can be a magnetic medium (e.g., a floppy disk, a hard disk, a tape), an optical medium (e.g., a DVD), or a semiconductor medium. The semiconductor medium can be a solid-state hard disk.

[0173] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0174] Those of ordinary skill in the art will appreciate that the units and algorithm steps of each example described in conjunction with the embodiments disclosed herein can be implemented in electronic hardware, or a combination of computer software and electronic hardware. Whether these functions are performed in hardware or software depends on the specific application and design constraints of the technical solution. Professional and technical personnel can use different methods to implement the described functions for each specific application, but such implementation should not be considered to be beyond the scope of this application.

[0175] In the several embodiments provided in the present application, it should be understood that the disclosed systems and methods can be implemented in other ways. For example, the embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or units, which can be electrical, mechanical or other forms.

[0176] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.

[0177] In addition, each functional unit in each embodiment of the present application may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit.

[0178] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any person skilled in the art who is familiar with the present technical field can easily think of changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

Claims

1. A method for follow-up management of otolaryngology patients, characterized in that: The specific steps include: Obtain the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans, establish the patient's personal file, and enter their symptom data and allergy history into the system; During the peak pollen season, we obtain symptom records of all patients and information on environmental pollen concentrations, analyze the information, assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and classify each patient based on the assessment results; According to the classification results of all patients, develop and implement personalized follow-up plans for low risk, medium risk and high risk respectively; Obtain dynamic information during the implementation of the follow-up plan, analyze it after acquisition, evaluate the implementation of the follow-up plan, and dynamically adjust the follow-up plan based on the evaluation results; Generate follow-up reports regularly and send them to doctors and patients, while providing patients with long-term health management advice.

2. The method for follow-up management of otolaryngology patients according to claim 1, characterized in that: During the peak pollen season, the symptom records of all patients and the environmental pollen concentration information are obtained and analyzed to assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration. The patients are then classified according to the assessment results, which specifically includes the following steps: During the peak pollen season, all patients were provided with symptom records and information on ambient pollen concentrations; Preprocessing of all patients’ symptom records and environmental pollen concentration information; Extracting the immune response data from the pre-processed symptom record information of each patient and the pollen concentration data from the environmental pollen concentration information, and analyzing them after extraction to generate the immune response fluctuation index and pollen concentration variation coefficient of each patient respectively; The generated immune response fluctuation index and pollen concentration variation coefficient of each patient are used to construct an aggravation risk assessment model to generate an aggravation risk coefficient for each patient. The generated aggravation risk coefficient for each patient is compared with the pre-set aggravation risk coefficient threshold range to evaluate the risk level of each patient's allergic symptoms aggravated by changes in pollen concentration, and each patient is classified according to the evaluation results.

3. The method for follow-up management of otolaryngology patients according to claim 2, characterized in that: The logic for obtaining the immune response fluctuation index and pollen concentration variation coefficient of each patient is as follows: Extract the immune response data from the pre-processed symptom record information of each patient, including the immunoglobulin level values ​​and corresponding time points of each patient at different times over a period of time, and use the function MYQDB according to the time series i (T) represents the time point, MYQDB i (T) represents the immunoglobulin level of the i-th patient at time T in a period of time, i = 1, 2, 3, ..., k, k is a positive integer, and the time period is defined as [T1, T2]; Perform Fourier transform on the immunoglobulin level of the i-th patient at time T within a period of time, according to the formula: In the formula, F(MYQDB i (T)) is the immunoglobulin level value MYQDB at time T in the immune response data of the i-th patient with worsening symptoms i (T) frequency component, T is the time variable, f is the frequency variable, and z is the imaginary unit; The amplitude of the Fourier transform result after taking the immunoglobulin level value of the i-th patient at time T within a period of time, that is, the absolute value |F(MYQDB i (T))|, represents the amplitude of the immunoglobulin level of the i-th patient at time T in a period of time at different frequencies; Calculate the immune response fluctuation index of each patient. The specific calculation formula is as follows: Where IRFI i is the immune response fluctuation index of the i-th patient; Extract pollen concentration data from the preprocessed environmental pollen concentration information, including the average pollen concentration of each patient's activity area at different times within a period of time, and calibrate the average pollen concentration of each patient's activity area at different times within a period of time as represents the average pollen concentration of the activity area of ​​the ith patient at time m within a period of time, m = 1, 2, 3, ..., g, where g is a positive integer; Calculate the mean and standard deviation of the average pollen concentration in the activity area of ​​each patient over a period of time according to the formula: In the formula, is the average pollen concentration of the i-th patient’s activity area over a period of time, is the standard deviation of the average pollen concentration in the activity area of ​​the ith patient over a period of time; Calculate the coefficient of variation of pollen concentration for each patient. The specific calculation formula is as follows: Where, PCVC i is the coefficient of variation of pollen concentration of the ith patient.

4. The method for follow-up management of otolaryngology patients according to claim 3, characterized in that: The immune response fluctuation index IRFI generated for each patient i and pollen concentration variation coefficient PCVC i Construct an exacerbation risk assessment model and generate the exacerbation risk coefficient ERC for each patient by weighted summation i , and the generated risk coefficient ERC for each patient i Compared with the pre-set aggravation risk factor threshold [ERC 1 , ERC 2 ] intervals to assess the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and to classify each patient based on the assessment results. The specific analysis is as follows: If ERC i <ERC 1 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is low risk, and the patient is classified as a low-risk patient; If ERC 1 ≤ERC i ≤ERC 2 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is medium risk, and the patient is classified as a medium-risk patient; If ERC i >ERC 2 , the patient's risk level of aggravation of allergic symptoms due to changes in pollen concentration is high, and the patient is classified as a high-risk patient.

5. The method for follow-up management of otolaryngology patients according to claim 4, characterized in that: According to the classification results of all patients, personalized follow-up plans for low risk, medium risk and high risk are formulated and implemented respectively, as follows: For low-risk patients, develop and implement a low-intensity follow-up plan and provide basic health guidance; For patients at medium risk, develop and implement a moderate intensity follow-up plan and provide targeted health guidance; For high-risk patients, develop and implement intensive follow-up plans, formulate emergency treatment plans, and provide comprehensive health guidance and preventive measures.

6. The method for follow-up management of otolaryngology patients according to claim 5, characterized in that: Obtain dynamic information during the implementation of the follow-up plan, analyze it after obtaining it, evaluate the implementation of the follow-up plan, and dynamically adjust the follow-up plan based on the evaluation results, which specifically includes the following steps: Obtain dynamic information during the implementation of the follow-up plan, including physiological parameter records and treatment compliance information of all patients; Pre-process the physiological parameter records and treatment compliance information of all patients; Extracting key physiological data from the preprocessed physiological parameter record information of each patient and medication record data from the treatment compliance information, and analyzing them after extraction to generate a physiological parameter fluctuation index and a treatment compliance coefficient for each patient respectively; The generated physiological parameter fluctuation index and treatment compliance coefficient of each patient are used to construct an execution evaluation model, and the execution evaluation coefficient of each patient is generated. The generated execution evaluation coefficient of each patient is compared with the pre-set execution evaluation coefficient threshold range to evaluate the implementation of the follow-up plan of each patient, and dynamically adjust the follow-up plan according to the evaluation results.

7. The method for follow-up management of otolaryngology patients according to claim 6, characterized in that: The logic for obtaining the physiological parameter fluctuation index and treatment compliance coefficient of each patient is as follows: Extract key physiological data from the pre-processed physiological parameter record information of each patient, including the blood oxygen saturation and corresponding time points of each patient at different times during the implementation of the follow-up plan, and use the function SPO according to the time series i (t), t is the time point, SPO i (t) represents the blood oxygen saturation of the ith patient at time t during the implementation of the follow-up plan, and the time period is defined as [t1, t2]; Perform Fourier transform on the blood oxygen saturation of the i-th patient at time t within a period of time, according to the formula: In the formula, F(SPO i (t)) is the blood oxygen saturation SPO of the i-th patient at time t within a period of time i (t) is the frequency component, where t is the time variable, j is the frequency variable, and d is the imaginary unit; Take the amplitude of the Fourier transform result of the blood oxygen saturation of the ith patient at time t within a period of time, that is, the absolute value |F(SPO i (t))|, represents the amplitude of the blood oxygen saturation of the i-th patient at time t within a period of time at different frequencies; Calculate the physiological parameter fluctuation index of each patient. The specific calculation formula is as follows: Where, PPFI i is the physiological parameter fluctuation index of the i-th patient; Extract the medication record data from the pre-processed treatment compliance information of each patient, including the total number of times each patient actually took medication at different times during a period of time during the implementation of the follow-up plan, and mark the total number of times each patient actually took medication during a period of time during the implementation of the follow-up plan as NA i , NA i It represents the total number of times the ith patient actually took medication during a period of time during the implementation of the follow-up plan; Obtain the total number of medications that each patient needs to take during the implementation of the follow-up plan, and mark the total number of medications that each patient needs to take during the implementation of the follow-up plan as NT i , NT i It represents the total number of medications that the i-th patient needs to take during a period of time during the implementation of the follow-up plan; Calculate the treatment compliance coefficient of each patient. The specific calculation formula is as follows: Where, TAC i is the treatment compliance coefficient of the ith patient.

8. The method for follow-up management of otolaryngology patients according to claim 7, characterized in that: The physiological parameter fluctuation index PPFI generated for each patient i and treatment adherence coefficient TAC i Construct an execution evaluation model and generate the execution evaluation coefficient EEC of each patient through weighted summation i , and the execution evaluation coefficient EEC of each patient generated i and the pre-set execution evaluation coefficient threshold interval [EEC 1 , EEC 2 ] to compare and evaluate the implementation of the follow-up plan for each patient, and dynamically adjust the follow-up plan based on the evaluation results. The specific analysis is as follows: If EEC i <EEC 1 , the patient's follow-up plan implementation is poor, and it is necessary to significantly increase the follow-up frequency of the follow-up plan, strengthen monitoring measures, and adjust the treatment plan; If EEC 1 ≤EEC i ≤EEC 2 The follow-up plan for this patient is generally implemented, and it is necessary to slightly increase the frequency of follow-up and strengthen monitoring measures, and adjust the treatment plan as needed; If EEC i >EEC 2 The follow-up plan for this patient is being implemented well. The follow-up frequency of the current follow-up plan will be maintained and no adjustments will be made to the follow-up plan.

9. An otolaryngology patient management and follow-up system, used to implement an otolaryngology patient management and follow-up method as described in any one of claims 1 to 8, characterized in that: It includes patient file management module, peak risk assessment module, personalized follow-up plan module, dynamic follow-up assessment module and intelligent follow-up report module; Patient file management module, which obtains the patient's basic information, medical records, allergy symptom descriptions, diagnosis results and treatment plans, establishes the patient's personal file, and enters his symptom data and allergy history into the system; Peak risk assessment module, during the peak pollen season, obtains and analyzes the symptom records of all patients and the environmental pollen concentration information, assesses the risk level of each patient's allergic symptoms being aggravated by changes in pollen concentration, and classifies each patient according to the assessment results; The personalized follow-up plan module develops and implements personalized follow-up plans for low-risk, medium-risk, and high-risk patients based on the classification results of all patients; Dynamic follow-up evaluation module, which obtains dynamic information of the follow-up plan during its implementation, analyzes it after acquisition, evaluates the implementation of the follow-up plan, and dynamically adjusts the follow-up plan based on the evaluation results; The intelligent follow-up report module generates follow-up reports regularly and sends them to doctors and patients, while providing patients with long-term health management advice.

Citation Information

Patent Citations

  • Medical follow-up visit method, device, equipment and medium

    CN116978584A

  • Intelligent follow-up visit method and device

    CN117238532A

  • Patient follow-up visit method and device based on artificial intelligence, terminal and medium

    CN118398246A

  • Medical condition management method and system

    US20160004834A1

Cited By

  • Intelligent remote follow-up visit method and system for tumor patients

    CN119541840A

  • Digital mobile medical treatment-based anaphylactic disease inquiry auxiliary system and method

    CN119694539A

  • Tumor patient follow-up visit management method and system based on Internet

    CN119943245A

  • Intelligent chronic disease management method and system

    CN119988500A

  • Intelligent follow-up visit method and system for heart failure patients at home

    CN120126825A